Ritlecitinib tosylate

甲磺酸利特希替尼

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameRitlecitinib tosylate
Drug Alias NameRitlecitinib tosilate甲苯磺酸利特昔替尼Ritlecitinib利特昔替尼LITFULO +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitorsTEC kinase family inhibitors
TargetsTyrosine-protein kinase JAK3TEC kinase family
Therapy Area/IndicationsChronic UrticariaVitiligoAlopecia Areata +[15] 
Global Approved IndicationsAlopecia Areata
Approved Indications in ChinaAlopecia Areata
Original Approved Country/TerritoryUnited States
Original Approved Date2023/06/23
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[43] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer (China) Research And Development Co LtdPfizer (Beijing) Research and Development Co LtdPfizer Inc +[8] 
Inactive CompaniesPfizer Ltd
Active IndicationsChronic UrticariaVitiligoAlopecia Areata +[8] 
Inactive IndicationsRenal InsufficiencyHepatic InsufficiencyColitis, Ulcerative +[7] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG